ContractK2 Therapeutics, Inc. • February 4th, 2015 • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
CIDARA THERAPEUTICS, INC. LOAN AND SECURITY AGREEMENTLoan and Security Agreement • February 4th, 2015 • K2 Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of December 29, 2014, by and between Comerica Bank (“Bank”) and Cidara Therapeutics, Inc., a Delaware corporation (“Borrower”).
July 12, 2014 BY EMAIL Jeff Stein 13525 Samantha Ave San Diego, CA 92129 Re: Amended and Restated Employment Agreement Dear Jeff:Employment Agreement • February 4th, 2015 • K2 Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This letter agreement (the “Agreement”) sets forth the terms of your continued employment as the President and Chief Executive Officer (“CEO”) of Cidara Therapeutics, Inc. (the “Company”). This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to me. As of its effective date this Agreement replaces and supersedes in its entirety the letter agreement between you and K2 Therapeutics, Inc. dated January 30, 2014 (the “Prior Agreement”) except that the terms of your Employee Confidentiality Assignment and Nonsolicitation Agreement executed on January 30, 2014 (the “Restrictive Covenant Agreement”) shall continue to apply.
Re: Employment AgreementEmployment Agreement • February 4th, 2015 • K2 Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This letter agreement (the “Agreement”) sets forth the terms of your employment as the Chief Commercial Officer (“CCO”) of CIDARA Therapeutics, Inc. (the “Company”). This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to me.
ASSET PURCHASE AGREEMENT ACQUISITION OF CERTAIN ASSETS OF SEACHAID PHARMACEUTICALS, INC. BY K2 THERAPEUTICS, INC. DATED AS OF MAY 30, 2014Asset Purchase Agreement • February 4th, 2015 • K2 Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This ASSET PURCHASE AGREEMENT is made as of May 30, 2014 by and between K2 THERAPEUTICS, INC., a Delaware corporation (“Purchaser”), and SEACHAID PHARMACEUTICALS, INC., a Delaware corporation (“Seller”).
CONSULTING AND INDEPENDENT CONTRACTOR AGREEMENTConsulting and Independent Contractor Agreement • February 4th, 2015 • K2 Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS AGREEMENT (“Agreement”) is made and entered into as of the 28th of January, 2015 (the “Effective Date”), by and between CIDARA THERAPEUTICS, INC. a Delaware corporation, (f/k/a K2 Therapeutics, Inc., the “Company”) and KEVIN JUDICE, an individual (“Consultant”). The Company desires to retain Consultant as an independent contractor to perform Services (defined below) for the Company and Consultant is willing to perform such Services, on terms set forth more fully below.
FIRST AMENDMENT TO LEASELease • February 4th, 2015 • K2 Therapeutics, Inc. • Biological products, (no disgnostic substances)
Nancy Ridge Technology Center, L.P., a California limited partnership (“Lessor”), and K2 Therapeutics, Inc., a Delaware corporation, (“Lessee”), hereby amend the Lease dated June 9, 2014 (the “Lease”) for Suites #101 and #102 at 6310 Nancy Ridge Drive and the downstairs of Suite #104 at 6330 Nancy Ridge Drive, San Diego, CA 92121 (“Premises”) as follows effective as of January 6, 2015:
